Terms: = Lung cancer AND uPA AND Staging
4 results:
1. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract] [Full Text] [Related]
2. Predicting the sites of metastases from lung cancer using molecular biologic markers.
D'Amico TA; Aloia TA; Moore MB; Conlon DH; Herndon JE; Kinch MS; Harpole DH
Ann Thorac Surg; 2001 Oct; 72(4):1144-8. PubMed ID: 11603427
[TBL] [Abstract] [Full Text] [Related]
3. Increased levels of urokinase receptor in plasma of head and neck squamous cell carcinoma patients.
Schmidt M; Hoppe F
Acta Otolaryngol; 1999; 119(8):949-53. PubMed ID: 10728940
[TBL] [Abstract] [Full Text] [Related]
4. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Pavey SJ; Marsh NA; Ray MJ; Butler D; Dare AJ; Hawson GA
Boll Soc Ital Biol Sper; 1996; 72(11-12):331-40. PubMed ID: 9178585
[TBL] [Abstract] [Full Text] [Related]
